Zhang R - Search Results

1

T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling.

Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. Weerasinghe P, et al. Among authors: zhang r. Prostate. 2008 Sep 15;68(13):1430-42. doi: 10.1002/pros.20807. Prostate. 2008. PMID: 18615483 Free PMC article.

2

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

Wang H, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: zhang r. Prostate. 2003 Feb 15;54(3):194-205. doi: 10.1002/pros.10187. Prostate. 2003. PMID: 12518324

3

Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.

Rayburn ER, Wang W, Zhang Z, Li M, Zhang R, Wang H. Rayburn ER, et al. Among authors: zhang r, zhang z. Prostate. 2006 Nov 1;66(15):1653-63. doi: 10.1002/pros.20485. Prostate. 2006. PMID: 16927305

4

Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.

Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R, Wang H. Wang W, et al. Among authors: zhang r. Prostate. 2008 Jun 1;68(8):809-19. doi: 10.1002/pros.20742. Prostate. 2008. PMID: 18324646

5

Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog.

Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang MH, Wang W, Zhang R. Zhang X, et al. Among authors: zhang r. Mar Drugs. 2012 May;10(5):1138-1155. doi: 10.3390/md10051138. Epub 2012 May 23. Mar Drugs. 2012. PMID: 22822362 Free PMC article.

6

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. Wang W, et al. Among authors: zhang r, zhang x. PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. PLoS One. 2012. PMID: 23028659 Free PMC article.

7

Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.

Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Wang W, et al. Among authors: zhang r. Gastroenterology. 2014 Oct;147(4):893-902.e2. doi: 10.1053/j.gastro.2014.07.001. Epub 2014 Jul 10. Gastroenterology. 2014. PMID: 25016295 Free PMC article.

8

Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.

Feng L, Yao HP, Wang W, Zhou YQ, Zhou J, Zhang R, Wang MH. Feng L, et al. Among authors: zhang r. Clin Cancer Res. 2014 Dec 1;20(23):6045-58. doi: 10.1158/1078-0432.CCR-14-0898. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294907

9

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.

Qin JJ, Wang W, Voruganti S, Wang H, Zhang WD, Zhang R. Qin JJ, et al. Among authors: zhang r, zhang wd. Oncotarget. 2015 Feb 20;6(5):2623-40. doi: 10.18632/oncotarget.3098. Oncotarget. 2015. PMID: 25739118 Free PMC article.

10

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.

Qin JJ, Wang W, Sarkar S, Voruganti S, Agarwal R, Zhang R. Qin JJ, et al. Among authors: zhang r. Oncotarget. 2016 May 31;7(22):32566-78. doi: 10.18632/oncotarget.8873. Oncotarget. 2016. PMID: 27105525 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36,642 results

Search Page

Filters